Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Recurrence 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 9130-nm albumin-bound paclitaxel 6S 1 (combination) 4Albumin-Bound Paclitaxel 4toripalimab 3Taxes 3Nivolumab 2Injections 2Drug Therapy 2surufatinib 1penpulimab 1pegylated granulocyte colony-stimulating factor 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1fluzoparib 1envafolimab 1endostar protein 1conteltinib 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Simvastatin 1Radiosurgery 1Paclitaxel 1Oxaliplatin 1Metformin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Pancreatic Cancer × fluzoparib × Gastrointestinal × Clear all
NCT04228601 2024-08-16

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
39 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡